Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 1 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00890747Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyTreatment